Alvotech (ALVO) Advances +20% in 30 Days as Biosimilar Pipeline Builds Momentum
Key Takeaways
- Alvotech (ALVO) shares have climbed roughly 20% over the last 30 days, moving from about $4.91 to around $5.89.
- The advance was driven by a rare Barclays double upgrade, Bank of America's Buy initiation, and FDA acceptance of the company's AVT80 biosimilar application.
- Over the last quarter the stock has risen about 69%, rebounding sharply from a mid-2026 low as manufacturing and regulatory overhangs eased.
- Investors are positioning ahead of anticipated FDA decisions in the fourth quarter of 2026 on biosimilars to Simponi, Eylea, and Prolia/Xgeva.
- Management has reaffirmed full-year 2026 guidance of $650–$700 million in revenue and $180–$220 million in adjusted EBITDA.
Alvotech's Niche in Biosimilars and Global Reach
Alvotech is a biotechnology company dedicated to developing and manufacturing biosimilar medicines. Founded by Robert Wessman, it targets lower-cost alternatives to major biologic therapies using an integrated approach that covers research, regulatory work, and large-scale production.
The company currently markets five approved biosimilars in various regions, covering reference products such as Humira, Stelara, Simponi, Eylea, and Prolia/Xgeva. Its pipeline spans autoimmune conditions, eye disorders, osteoporosis, respiratory issues, and oncology. Distribution relies on partners including TEVA, Sandoz, and Dr. Reddy's Laboratories to serve the United States, Europe, Japan, and additional markets.
ALVO Stock Performance: +20% Over 30 Days and +69% This Quarter
In the past 30 days, ALVO has moved up approximately 20%, advancing from a late-August close near $4.91 to around $5.89. The gains have come in sharp, event-driven bursts rather than a gradual climb, highlighted by a 7.9% jump in a single mid-September session.
Looking back over the quarter, the picture strengthens further. Three months prior the shares closed near $3.48, translating to roughly 69% appreciation. This recovery stands out after the stock traded under pressure for much of the first half of 2026, hovering close to its 52-week low of $2.94 amid manufacturing and approval concerns.
Catalysts Behind the Recent 30-Day Gain
Multiple concrete developments fueled the latest advance. Barclays issued a double upgrade in mid-September, with analyst Glen Santangelo moving the rating to Overweight from Underweight and lifting the price target to $8 from $4, based on expectations for three FDA approvals later this year. The stock rose 7.9% on that news, its largest one-day gain in months.
Bank of America started coverage with a Buy rating and $7 target, describing the company as nearing an inflection point where focus shifts from regulatory questions to commercial execution. The FDA also accepted the Biologics License Application for AVT80, a proposed biosimilar to Entyvio in prefilled syringe and pen formats. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Quarterly Rebound and Easing Headwinds
The broader quarterly move reflects resolution of the main issues that weighed on the shares earlier in 2026: manufacturing compliance and U.S. approval timelines. In July the FDA closed its inspection of the Reykjavik facility with a Voluntary Action Indicated classification, removing a key hurdle.
Around the same period the company resubmitted applications for AVT05 (biosimilar to JNJ Simponi), AVT06 (biosimilar to REGN Eylea), and AVT03 (biosimilar to AMGN Prolia/Xgeva). Leadership transitioned with Lisa Graver becoming CEO in late March 2026, and the balance sheet was bolstered by about $165 million in equity proceeds plus a $75 million term loan. Although first-half revenue declined year over year due to manufacturing slowdowns, management stood by its full-year outlook, helping stabilize sentiment.
Near-Term Catalysts and Items to Monitor
The main upcoming driver remains the FDA review of the Simponi, Eylea, and Prolia/Xgeva biosimilar applications, with decisions expected on or before December 4, 2026. Approval timing along with any intellectual-property outcomes will influence U.S. launch plans.
Attention will also turn to third-quarter results and commentary on manufacturing progress, as the fourth quarter is expected to be the strongest period once supply normalizes. Other areas include advancement on the Entyvio program, the high-dose Eylea candidate, and the FUJIFILM Biotechnologies partnership slated to add U.S. capacity from late 2027 onward. From what I see, pricing and reimbursement trends in the biosimilar space continue to warrant close attention.
Tracking Market Setups with Tickeron Tools
In my view, combining fundamental analysis with algorithmic signals can add useful perspective when following names like this one. Tickeron’s AI Trend Prediction Engine has been a tool I turn to occasionally for an additional data layer on price behavior and pattern recognition across a wide range of equities.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ALVO in +10.11% Uptrend, rising for three consecutive days on September 21, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ALVO advanced for three days, in 187 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ALVO as a result. In 62 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
The 50-day moving average for ALVO moved above the 200-day moving average on September 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Aroon Indicator entered an Uptrend today. In 109 of 163 cases where ALVO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.
Bearish Trend Analysis
The 10-day RSI Indicator for ALVO moved out of overbought territory on September 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 19 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 40 cases where ALVO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for ALVO turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 33 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
ALVO broke above its upper Bollinger Band on September 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. ALVO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (43.873). P/E Ratio (42.450) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (3.071) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement